Mr. Speaker, according to a journal of the American Association for the Advancement of Science, that might not be the only reason.
It reports that African trials of this Canadian vaccine have in fact been delayed, not because of logistical problems but over an intellectual property dispute. The company that owns the commercial licence for the drug is said to be dragging its feet.
With thousands of lives at risk, can the Minister of Health explain what Canada is doing to ensure this vaccine gets to the people who need it immediately?